Marc Garidel - Ipsen SA Chairman, CEO and Chairman of Strategic Committee

IPN Stock  EUR 109.20  0.90  0.83%   

Chairman

Mr. Marc de Garidel serves as NonExecutive Chairman of Ipsen SA. He serves as NonExecutive Chairman at the firm since November 22, 2010. He was Chief Executive Officer of Ipsen SA from November 22, 2010 to July 18, 2016. He is also Member of the Company Strategic Committee. Until August 2014, he oversaw as General Manager the Company United States EndocrinologyOncology Business Unit. Mr. de Garidel started his career in 1983 with the Eli Lilly pharmaceutical Group. He held various roles, mainly Finance related, firstly in France, then in the United States and in Germany. In 1995, he joined Amgen, the American biotech Group, as Vice President, Finance and Treasury for Europe. In 1998, he was appointed at Amgen headquarters in California as Vice President, Corporationrationrate Controller and Chief Accounting Officer. In 2000, he became Vice President, General Manager for France, in charge of general management of Amgen France. In 2006, he was appointed Vice President of Southwestern Europe comprising France, Spain, Belgium, and Portugal. In addition, he served as President of the Biotech Committee of the French Pharmaceuticals Association from 2003 to 2006. He was appointed Vice President from 2006 and President in 2010 of European Biopharmaceutical Enterprises. He holds a teaching position at Ecole Centrale de Paris and at ESSEC Business School since 2008 and was awarded with the title of a Chevalier de la Legion dHonneur since 2016.
Age 61
Tenure 8 years
Phone33 1 58 33 50 00
Webhttps://www.ipsen.com
de Garidel currently also holds the posts of Chairman of Ipsen Pharma SAS, Suraypharm SAS and G5 Sante, as well as NonExecutive Chairman of Promethera. He graduated from Ecole Superieure des Travaux Publics with a degree in Civil Engineering and he also obtained a Business degree at Thunderbird School of Global Management in Arizona, the United States.

Ipsen SA Management Efficiency

The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 667 M in total debt with debt to equity ratio (D/E) of 0.45, which is about average as compared to similar companies. Ipsen SA has a current ratio of 1.55, which is within standard range for the sector. Debt can assist Ipsen SA until it has trouble settling it off, either with new capital or with free cash flow. So, Ipsen SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ipsen SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ipsen to invest in growth at high rates of return. When we think about Ipsen SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

CHAIRMAN Age

JeanRene FourtouVivendi SA
76
Vincent BolloreVivendi SA
65
Henri LachmannVivendi SA
76
Mohamed BoussaidItissalat Al Maghrib
51
Abdeslam AhizouneItissalat Al Maghrib
68
Eissa SuwaidiItissalat Al Maghrib
56
Simon GillhamVivendi SA
62
Abdulsalam AhizouneItissalat Al Maghrib
61
Arnaud PuyfontaineVivendi SA
54
Ipsen S.A. operates as a biopharmaceutical company worldwide. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. IPSEN operates under Drug ManufacturersSpecialty Generic classification in France and is traded on Paris Stock Exchange. It employs 5700 people. Ipsen SA (IPN) is traded on Euronext Paris in France and employs 5,000 people.

Management Performance

Ipsen SA Leadership Team

Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Herve Couffin, Independent Director
Helene AuriolPotier, Director
Carol Xueref, Independent Director
Richard Paulson, Executive Vice President and Chief Executive Officer of Ipsen North America
Yan Moore, Senior Vice President Head of Oncology Therapeutics Area
James Levine, President
Margaret Liu, Independent Director
Claude Bertrand, Chief Scientific Officer and Executive VP of RandD
Stephane Bessette, Executive Vice President of Human Resources
Christel Bories, Deputy CEO
Howard Mayer, Executive Vice President, Head of Research & Development
Christophe Verot, Director
Regis Mulot, Chief Human Resource Officer, Executive Vice President
Jean Fabre, Executive Vice President - Primary Care Business Unit, Member of the Executive Committee
David Meek, Chief Executive Officer, Director
Alexander McEwan, Vice President and Head of Radiopharmaceuticals
Etienne Blois, Vice President Latin America, Spain and Portugal
Ivana MagovcevicLiebisch, Executive Vice President Chief Business Officer
Philippe Bonhomme, Director, Permanent representative of Beech Tree SA
Heather White, Vice President Global Internal Audit
Martha Crawford, Independent Director
Harout Semerjian, Executive Vice President & President Specialty Care International & Global Franchises
Anne Beaufour, Director, Permanent representative of Highrock S.àr.l.
Christopher Masterson, Senior Vice President Quality
Benoit Hennion, Executive Vice President and President Consumer Helathcare
Antoine Flochel, Vice Chairman of the Board
Marc Garidel, Chairman, CEO and Chairman of Strategic Committee
Paul Sekhri, Independent Director
Henri Beaufour, Director
Gwenan White, Executive Vice President Communications and Public Affairs
Francois Garnier, Executive Vice President General Counsel, Member of the Executive Committee
Ivana Magovcevic, Executive Vice President Chief Business Officer
Dominique Bery, Executive Vice President, Strategy and Transformation
Alexandre LeBeaut, Executive Vice President Research & Development, Chief Scientific Officer
Pierre Boulud, Executive Vice President - Specialty Care Commercial Operations, Member of the Executive Committee
Aidan Murphy, Executive Vice-President Technical Operations
Piet Wigerinck, Independent Director
David Loew, Chief Executive Officer, Director
Craig Marks, VicePres Relations
Pierre Martinet, Independent Director
Yan MD, VP Area
Jonathan Barnsley, Executive Vice-President Technical Operations, Member of the Executive Committee
Dominique Brard, Executive Vice President - Human Resources and Member of the Executive Committee
FrancoisMaurice Garnier, Executive Vice President General Counsel
Cynthia Schwalm, the United States General Manager
Philippe RobertGorsse, Executive Vice President - Specialty Care Franchises, Member of the Executive Committee
Michele Ollier, Independent Director
Carol Stuckley, Independent Director
JeanMarc Parant, Director, representing Employees
Steven Hildemann, Executive Vice President Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance
Christophe Jean, Executive Vice President - Group Strategy and Business Development, Member of the Executive Committee
Philippe LopesFernandes, Executive Vice President Chief Business Officer
Aymeric Chatelier, Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President
Didier Veron, Senior Vice President Public Affairs and Corporate Communication
Eugenia Litz, Vice President of Investor Relations
Dominique Laymand, Executive Vice President, Chief Ethics and Compliance Officer
Stephan Gagne, Head Office

Ipsen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ipsen SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Ipsen Stock analysis

When running Ipsen SA's price analysis, check to measure Ipsen SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ipsen SA is operating at the current time. Most of Ipsen SA's value examination focuses on studying past and present price action to predict the probability of Ipsen SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ipsen SA's price. Additionally, you may evaluate how the addition of Ipsen SA to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bonds Directory
Find actively traded corporate debentures issued by US companies
Please note, there is a significant difference between Ipsen SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ipsen SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ipsen SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.